Dabogratinib (Onc)
Non-Muscle Invasive Bladder Cancer (NMIBC)
Key Facts
About Tyra Biosciences
Tyra Biosciences is a clinical-stage biotech focused on developing next-generation, selective FGFR inhibitors for oncology and genetically defined skeletal conditions. Its core value proposition is its proprietary SNÅP discovery platform, which enables rapid, structure-based drug design to tackle resistance mutations and improve selectivity. The company has built a robust pipeline led by oral dabogratinib, now in Phase 2 for achondroplasia and with IND clearance for bladder cancer, supported by a strong team with deep drug development and commercialization expertise.
View full company profileAbout Tyra Biosciences
Tyra Biosciences is a clinical-stage biotech focused on developing next-generation, selective FGFR inhibitors for oncology and genetically defined skeletal conditions. Its core value proposition is its proprietary SNÅP discovery platform, which enables rapid, structure-based drug design to tackle resistance mutations and improve selectivity. The company has built a robust pipeline led by oral dabogratinib, now in Phase 2 for achondroplasia and with IND clearance for bladder cancer, supported by a strong team with deep drug development and commercialization expertise.
View full company profileTherapeutic Areas
Other Non-Muscle Invasive Bladder Cancer (NMIBC) Drugs
| Drug | Company | Phase |
|---|---|---|
| FL115 | Forlong Biotechnology | Phase 2 |
| Fosciclopirox (Ciclopirox Prodrug) | CicloMed | Pre-clinical/Phase 1 |
| Vesique® (APL-1202) | Asieris Pharmaceuticals | Phase 3 |
| DPX-formulated Products | BioVaxys | Phase 1 |
| Alpha1H | Hamlet Biopharma | Phase 2 |
| LiPax | LIPAC Oncology | Phase 2 |
| VAX014 | Vaxiion Therapeutics | Phase 1/2 |
| ZH9 | Prokarium | Phase 1 |
| NDV-01 | Relmada Therapeutics | Phase 2/3 |
| VDC Platform | Aura Biosciences | Preclinical |